Eli Lilly (LLY): FY24 Q4 earnings call, Feb 6, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Feb 6, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
5 matches for “Omvoh”; 5 quoted, at least 25 words apart.
…pipeline milestones. We received approval for a new indication of Zepbound and Omvoh. We submitted imlunestrant for metastatic breast cancer and tirzepatide for heart failure.…
…revenue grew 27% in constant currency. Volume growth was driven by Mounjaro, Omvoh, Jardiance and Verzenio. In China, revenue increased 13% in constant currency. Tyvyt…
…was $114 million, adding another solid quarter of sequential revenue growth. Worldwide Omvoh revenue increased to $57 million. With the recent FDA approval in Crohn's…
…neuroscience and immunology to also grow revenue in 2025 as Ebglyss, Jaypirca, Omvoh and Kisunla launch upticks continue. At the portfolio level, we anticipate foreign…
…the U.S., Zepbound for obstructive sleep apnea in adults with obesity and Omvoh for moderate to severe Crohn's disease. Both approvals are important milestones and…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-02-06:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-02-06:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP